Page last updated: 2024-11-03

ag 1879 and Cardiac Hypertrophy

ag 1879 has been researched along with Cardiac Hypertrophy in 1 studies

3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Marin, TM1
Clemente, CF1
Santos, AM1
Picardi, PK1
Pascoal, VD1
Lopes-Cendes, I1
Saad, MJ1
Franchini, KG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis[NCT02737202]Phase 228 participants (Actual)Interventional2016-04-30Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for ag 1879 and Cardiac Hypertrophy

ArticleYear
Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Circulation research, 2008, Oct-10, Volume: 103, Issue:8

    Topics: Animals; Animals, Newborn; Cardiomegaly; Cell Size; Cells, Cultured; Extracellular Signal-Regulated

2008